A Phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases

Body, Jean-Jacques, Greipp, Philip, Coleman, Robert E., Facon, Thierry, Geurs, Filip, Fermand, Jean-Paul, Harousseau, Jean-Luc, Lipton, Allan, Mariette, Xavier, Williams, Catherine D., Nakanishi, Arline, Holloway, Donna, Martin, Steven W., Dunstan, Colin R., Bekker, Pirow J.·2003·Cancer

DOI 10.1002/cncr.11138

Cited by (384)

Items 101–200 of 384

Cellular Mechanisms of Multiple Myeloma Bone Disease
Angela Oranger, Claudia Carbone, M. Izzo, Maria Grano · 2013 · Clinical and Developmental Immunology
Mechanisms of bone invasion and metastasis in human neuroblastoma
Yasuyoshi Sohara, Hiroyuki Shimada, Yves Albert DeClerck · 2005 · Cancer Letters
Invasion-Related Factors as Potential Diagnostic and Therapeutic Targets in Oral Squamous Cell Carcinoma—A Review
B. S. M. S. Siriwardena, Takaaki Tsunematsu, Guangying Qi, Naozumi Ishimaru, Yasusei Kudo · 2018 · International Journal of Molecular Sciences
OPG/membranous–RANKL complex is internalized via the clathrin pathway before a lysosomal and a proteasomal degradation
Tat, Steeve Kwan, Padrines, Marc, Theoleyre, Sandrine, Couillaud-Battaglia, Severine, Heymann, Dominique, Redini, Françoise, Fortun, Yannick · 2006 · Bone
Inhibition of RANKL as a treatment for osteoporosis: Preclinical and early clinical studies
Michael R. McClung · 2006 · Current Osteoporosis Reports
Pharmacological management of osteogenesis
Valeria Nardone, Federica D’Asta, Maria Luisa Brandi · 2014 · Clinics
RANK ligand and the regulation of skeletal remodeling
Norman H. Bell · 2003 · Journal of Clinical Investigation
Mechanism of bone metastasis: The role of osteoprotegerin and of the host-tissue microenvironment-related survival factors
Sofia Fili, Maria Karalaki, Bernhard J. Schaller · 2009 · Cancer Letters
Genetic deletion of muscle RANK or selective inhibition of RANKL is not as effective as full-length OPG-fc in mitigating muscular dystrophy
Dufresne, Sébastien S., Boulanger-Piette, Antoine, Bossé, Sabrina, Argaw, Anteneh, Hamoudi, Dounia, Marcadet, Laetitia, Gamu, Daniel, Fajardo, Val A., Yagita, Hideo, Penninger, Josef M. et al. · 2018 · Acta Neuropathologica Communications
A RANKL G278R mutation causing osteopetrosis identifies a functional amino acid essential for trimer assembly in RANKL and TNF
Eleni K. Douni, Vagelis E. Rinotas, Eleni Makrinou, Jochen Zwerina, Josef Martin Penninger, Elias Eliopoulos, Georg Andreas Schett, George A. Kollias · 2011 · Human Molecular Genetics
Differential modulation of RANKL isoforms by human osteoarthritic subchondral bone osteoblasts: Influence of osteotropic factors
Steeve Kwan Tat, Jean‐Pierre Pelletier, Daniel Lajeunesse, Hassan Fahmi, N. Duval, Johanne Martel‐Pelletier · 2008 · Bone
Protection against osteoporosis by active immunization with TRANCE/RANKL displayed on virus-like particles.
Spohn, Gunther, Schwarz, Katrin, Maurer, Patrik, Illges, Harald, Rajasekaran, Narendiran, Choi, Yongwon, Jennings, Gary T, Bachmann, Martin F · 2005 · The Journal of Immunology
RANK ligand inhibition with denosumab for the management of osteoporosis
Edward Michael Lewiecki · 2006 · Expert Opinion on Biological Therapy
Biochemical markers in oncology. Part I: Molecular basis. Part II: Clinical uses
Nathalie Voorzanger‐Rousselot, Patrick Garnero · 2007 · Cancer Treatment Reviews
The effects of RANK blockade and osteoclast depletion in a model of pure osteoblastic prostate cancer metastasis in bone
Peter G. Whang, Edward M. Schwarz, Seth C. Gamradt, William C. Dougall, Jay R. Lieberman · 2005 · Journal of Orthopaedic Research®
Osteoprotegerin in breast cancer: beyond bone remodeling
Michael Weichhaus, Stephanie Tsang Mui Chung, Linda Connelly · 2015 · Molecular Cancer
Association of polymorphisms of the osteoprotegerin gene with bone mineral density in Japanese women but not men
Yoshiji Yamada · 2003 · Molecular Genetics and Metabolism
Exogenous Administration of 15d-PGJ2–Loaded Nanocapsules Inhibits Bone Resorption in a Mouse Periodontitis Model
Marcelo Henrique Napimoga, Carlos Antônio Trindade‐da‐Silva, Vanessa Carregaro, Thaís Soares Farnesi-de-Assunção, Poliana Mendes Duarte, Nathalie Ferreira Silva de Melo, Leonardo Fernandes Fraceto · 2012 · The Journal of Immunology
The pharmacokinetics and pharmacodynamics of denosumab in patients with advanced solid tumours and bone metastases: a systematic review
Winnie Y. Sohn, Mary Ann Simiens, Kelly Jaeger, Shauna Hutton, Graham R. Jang · 2014 · British Journal of Clinical Pharmacology
Enhancement of periodontal tissue regeneration by transplantation of osteoprotegerin-engineered periodontal ligament stem cells
Fang Su, Shisen Liu, Junli Ma, Dongsheng Wang, E Lingling, Hongchen Liu · 2015 · Stem Cell Research & Therapy
Glycosaminoglycans as Potential Regulators of Osteoprotegerin Therapeutic Activity in Osteosarcoma
François Lamoureux, Gaelle Genevieve Alice Picarda, Laure Garrigue‐Antar, Marc Baud’huin, Valérie Trichet, André Vidal, Elisabeth Miot-Noirault, Bruno Pitard, Dominique Heymann, Françoise Rédiní · 2009 · Cancer Research
Bone markers in multiple myeloma
Ulrike Heider, Claudia Fleissner, Ivana Zavrski, Martin Kaiser, Monica Hecht, Christian Jakob, Orhan Sezer · 2006 · European Journal of Cancer
New insights into the pathophysiology and management of bone disease in multiple myeloma
Evangelos Terpos, Marianna Politou, Amin Rahemtulla · 2003 · British Journal of Haematology
Concordance of preclinical and clinical pharmacology and toxicology of monoclonal antibodies and fusion proteins: soluble targets
Pauline L. Martin, Peter J. Bugelski · 2011 · British Journal of Pharmacology
Denosumab for the treatment of bone metastases in breast cancer: evidence and opinion
Guenther G. Steger, Rupert Bartsch · 2011 · Therapeutic Advances in Medical Oncology
Myeloma bone disease: Pathogenetic mechanisms and clinical assessment
Franco Silvestris, Lucia Lombardi, Monica De Matteo, Arianna Bruno, Franco Dammacco · 2006 · Leukemia Research
Crosstalk between bone niche and immune system: Osteoimmunology signaling as a potential target for cancer treatment
Carmen Criscitiello, Giulia Viale, Lucia Gelao, Angela Espósito, Michelino De Laurentiis, Sabino De Placido, Michele L Santangelo, Aron Goldhirsch, Giuseppe Curigliano · 2014 · Cancer Treatment Reviews
The High Rate of Bone Resorption in Multiple Myeloma is due to RANK (Receptor Activator of Nuclear Factor-κB) and RANK Ligand Expression
Sophie Roux, Xavier Mariette · 2004 · Leukemia & lymphoma/Leukemia and lymphoma
Local Delivery of Recombinant Osteoprotegerin Enhances Postorthodontic Tooth Stability
James Bradley Hudson, Nan E. Hatch, Takayuki Hayami, Jae Min Shin, Marina Stolina, Paul J. Kostenuik, Sunil Kapila · 2012 · Calcified Tissue International
The RANKL inhibitor OPG-Fc increases cortical and trabecular bone mass in young gonad-intact cynomolgus monkeys
Michael S. Ominsky, Paul J. Kostenuik, P. Cranmer, S. Y. Smith, John E. Atkinson · 2007 · Osteoporosis International
The RANKL/RANK system as a therapeutic target for bone invasion by oral squamous cell carcinoma
Eijiro Jimi, Masashi Shin, HIROYUKI FURUTA, Yukiyo Tada, Jingo Kusukawa · 2013 · International Journal of Oncology
Targeting RANKL in breast cancer: bone metastasis and beyond
Hamdy A. Azim, Hatem A. Azim · 2013 · Expert Review of Anticancer Therapy
Painful Rheumatoid Arthritis
Pya Seidner · 2011 · Pain Physician
High serum values of soluble CD154, IL‐2 receptor, RANKL and osteoprotegerin in Langerhans cell histiocytosis
Rumiko Ishii, Akira Morimoto, Satoshi Ikushima, Tohru Sugimoto, Keiko Asami, Fumio Bessho, Kazuko Kudo, Yukiko Tsunematu, Junichiro Fujimoto, Shinsaku Imashuku · 2005 · Pediatric Blood & Cancer
Skeletal and extraskeletal actions of denosumab
Kathrin Sinningen, Elena A. Tsourdi, Martina Rauner, Tilman D. Rachner, Christine Hamann, Lorenz Christian Hofbauer · 2012 · Endocrine
Gravitational and Space Biology
William J. Landis · 2005
The role of markers of bone remodeling in multiple myeloma
Evangelos Terpos, Marianna Politou, Amin Rahemtulla · 2004 · Blood Reviews
Gene therapy methods in bone and joint disorders
Michael Ulrich‐Vinther · 2007 · Acta Orthopaedica
Mechanisms modulating inflammatory osteolysis: A review with insights into therapeutic targets
Wei Shi, Gene P. Siegal · 2008 · Pathology - Research and Practice
Pathobiology and management of prostate cancer-induced bone pain: recent insights and future treatments
Arjun Muralidharan, Maree Therese Smith · 2013 · Inflammopharmacology
Juvenile Paget disease
Stergios A. Pοlyzos, Tim Cundy, Christos Socrates Mantzoros · 2017 · Metabolism
The effect of zoledronic acid and osteoprotegerin on growth of human lung cancer in the tibias of nude mice
Sarah H. Tannehill‐Gregg, Andrea L. Levine, Murali V.P. Nadella, Haruo Iguchi, Thomas J. Rosol · 2006 · Clinical & Experimental Metastasis
A new xenograft model of myeloma bone disease demonstrating the efficacy of human mesenchymal stem cells expressing osteoprotegerin by lentiviral gene transfer
Neil K. Rabin, Charalampia A. Kyriakou, L. Coulton, Orla Gallagher, Clive Buckle, Reuben Benjamin, Nalini Singh, Janet Glassford, Takemi Otsuki, Amit Chunilal Nathwani et al. · 2007 · Leukemia
Pathophysiology of RANK ligand (RANKL) and osteoprotegerin (OPG)
Lorenz Christian Hofbauer · 2006 · Annales d Endocrinologie
Influence of RANKL inhibition on immune system in the treatment of bone diseases
Anne Fouque-Aubert, Roland D Chapurlat · 2007 · Joint Bone Spine
B cell acute lymphoblastic leukemia cells mediate RANK-RANKL–dependent bone destruction
Sujeetha A. Rajakumar, Eniko Papp, Kathy K. Lee, Ildiko Grandal, Daniele Merico, Careesa C. Liu, Bedilu A. Allo, Lucia Zhang, Marc D. Grynpas, Mark David Minden et al. · 2020 · Science Translational Medicine
Pathogenesis and Prevention of Bone Loss in Patients Who Have Kidney Disease and Receive Long-Term Immunosuppression
John Cunningham · 2006 · Journal of the American Society of Nephrology
The effects of RANKL inhibition on fracture healing and bone strength in a mouse model of osteogenesis imperfecta
Demetris Delos, Xu Yang, Benjamin F. Ricciardi, Elizabeth R. Myers, Mathias P. Bostrom, Nancy L. Pleshko · 2007 · Journal of Orthopaedic Research®
Denosumab for the management of bone disease in patients with solid tumors
Jean‐Jacques Body · 2011 · Expert Review of Anticancer Therapy
Painful Boney Metastases
Howard S. Smith, Robert L. Barkin · 2013 · American Journal of Therapeutics
Therapeutic implications of osteoprotegerin
Sofia Fili, Maria Karalaki, Bernhard J. Schaller · 2009 · Cancer Cell International
Biochemical markers of bone metabolism in multiple myeloma
Evangelos Terpos · 2006 · Cancer Treatment Reviews
Treatment strategies for bone disease
G. David Roodman · 2007 · Bone Marrow Transplantation
Osteoprotegerin Inhibits Calcification of Vascular Smooth Muscle Cell via Down Regulation of the Notch1-RBP-Jκ/Msx2 Signaling Pathway
Shaoqiong Zhou, Xing Fang, Huaping Xin, Wei Li, Hongyu Qiu, Siming Guan · 2013 · PLoS ONE
Osteoprotegerin expression in triple‐negative breast cancer cells promotes metastasis
Michael Weichhaus, Prabu Segaran, A. Renaud, Dirk Geerts, Linda Connelly · 2014 · Cancer Medicine
Osteoprotegerin and kidney disease
Alejandra Montanez-Barragan, Isaias Gómez-Barrera, María Dolores Sánchez-Niño, Alvaro Conrado Ucero, Liliana González–Espinoza, Alberto Ortíz · 2014 · Journal of Nephrology
Inhibition of bone resorption and growth of breast cancer in the bone microenvironment
Jeroen T. Buijs, Ivo Que, Clemens W.G.M. Löwik, Socrates E. Papapoulos, Gabri van der Pluijm · 2008 · Bone
Regulation of osteoprotegerin pro- or anti-tumoral activity by bone tumor microenvironment
François Lamoureux, Gatien Moriceau, Gaelle Genevieve Alice Picarda, Julie Rousseau, Valérie Trichet, Françoise Rédiní · 2009 · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
New Potential Targets for Treating Myeloma Bone Disease
G. David Roodman · 2006 · Clinical Cancer Research
The inhibition of RANKL/RANK signaling by osteoprotegerin suppresses bone invasion by oral squamous cell carcinoma cells
Masashi Shin, Keitaro Matsuo, T. Tada, Hidefumi Fukushima, H. Furuta, Satoru Ozeki, Tomoko Kadowaki, Ken Yamamoto, M. Okamoto, Eijiro Jimi · 2011 · Carcinogenesis
Bone metastasis in breast cancer: The story of RANK-Ligand
Hamdy A. Azim, Nermine Shawky Kamal, Hatem A. Azim · 2012 · Journal of the Egyptian National Cancer Institute
The Receptor Activator of Nuclear Factor-κB Ligand Inhibitor Osteoprotegerin Is a Bone-Protective Agent in a Rat Model of Chronic Renal Insufficiency and Hyperparathyroidism
J. Padagas, Matthew Colloton, Victoria Shalhoub, Paul J. Kostenuik, Sean Morony, Louis Munyakazi, M. Guo, D. Gianneschi, Edward M. Shatzen, Zhaopo Geng et al. · 2005 · Calcified Tissue International
Novel targets for myeloma bone disease
G. David Roodman · 2008 · Expert Opinion on Therapeutic Targets
Suppression of polyethylene particle–induced osteolysis by exogenous osteoprotegerin
Fabian von Knoch, Anja Heckelei, Christian Wedemeyer, Guido Saxler, Gero Hilken, Jochen Brankamp, Thomas Sterner, Stefan Landgraeber, Frank Henschke, F. Löer et al. · 2005 · Journal of Biomedical Materials Research Part A
RANKL inhibition for the management of patients with benign metabolic bone disorders
Athanasios D. Anastasilakis, Konstantinos A. Toulis, Stergios A. Pοlyzos, Evangelos Terpos · 2009 · Expert Opinion on Investigational Drugs
Myeloma and bone disease: "the dangerous tango".
Joshua Epstein, Ronald C. Walker · 2006 · PubMed
The clinical significance of serum markers of bone turnover in NSCLC patients: surveillance, management and prognostic implications.
Evangelos Terpos, Maria Kiagia, Eleni M. Karapanagiotou, Adrianni Charpidou, Kaliopi D Dilana, Efthimia G. Nasothimiou, Kevin Joseph Harrington, Aris Polyzos, Kostas Syrigos · 2009 · PubMed
RANKL inhibition: Clinical implications for the management of patients with multiple myeloma and solid tumors with bone metastases
Evangelos Terpos, Eleni Efstathiou, Dimitrios Christoulas, Μαρία Ρούσσου, Eirini Katodritou, Meletios Athanasios Dimopoulos · 2009 · Expert Opinion on Biological Therapy
Development of Small-Molecules Targeting Receptor Activator of Nuclear Factor-κB Ligand (RANKL)—Receptor Activator of Nuclear Factor-κB (RANK) Protein–Protein Interaction by Structure-Based Virtual Screening and Hit Optimization
Min Jiang, Lei Peng, Kai Yang, Tianqi Wang, Xueming Yan, Tao Jiang, Jianrong Xu, Qi Jin, Hanbing Zhou, Niandong Qian et al. · 2019 · Journal of Medicinal Chemistry
Anti‐RANKL therapy for inflammatory bone disorders: Mechanisms and potential clinical applications
Allen Anandarajah, Edward M. Schwarz · 2005 · Journal of Cellular Biochemistry
Denosumab Treatment for Juvenile Paget's Disease: Results From Two Adult Patients With Osteoprotegerin Deficiency (“Balkan” Mutation in theTNFRSF11BGene)
Stergios A. Pοlyzos, Panagiotis N. Singhellakis, Dorit Naot, Fotini Adamidou, Fotini Ch. Malandrinou, Athanasios D. Anastasilakis, Vaia Polymerou, Marina D. Kita · 2014 · The Journal of Clinical Endocrinology & Metabolism
Clinical usefulness of bone markers in prostate cancer with bone metastasis
Naoto Kamiya, Hiroyoshi Suzuki, Takumi Endo, Masashi Yano, Makito Naoi, Daisuke Nishimi, Koji Kawamura, Takashi Imamoto, Tomohiko Ichikawa · 2012 · International Journal of Urology
Prognostic Significance of Bone Markers in Patients With Lung Cancer Metastatic to the Skeleton: A Review of Published Data
Giannis Mountzios, V. Ramfidis, Evangelos Terpos, Kostantinos N. Syrigos · 2011 · Clinical Lung Cancer
Vitamin D and Osteoclastogenesis
Hisataka Yasuda, Kanji Higashio, Tatsuo Suda · 2005 · Elsevier eBooks
Anti-RANKL therapy for bone tumours: Basic, pre-clinical and clinical evidences
Dominique Heymann · 2012 · Journal of bone oncology
Novel targets in bone and cartilage
Christian Beyer, Georg Andreas Schett · 2010 · Best Practice & Research Clinical Rheumatology
Denosumab: an investigational drug for the management of postmenopausal osteoporosis
Michael E. Lewiecki · 2008 · Biologics
Receptor Activator for Nuclear Factor kappa B Ligand (RANKL) as an osteoimmune key regulator in bone physiology and pathology
Paola Narducci, Renato Bareggi, Vanessa Nicolin · 2009 · Acta Histochemica
New therapeutic agents for the treatment of bone diseases
Allan Lipton · 2005 · Expert Opinion on Biological Therapy
Harnessing the versatile role of OPG in bone oncology: counterbalancing RANKL and TRAIL signaling and beyond
Maria V. Deligiorgi, Mihalis I. Panayiotidis, John Grınıatsos, Dimitrios T. Trafalis · 2019 · Clinical & Experimental Metastasis
Retrovirus‐Mediated Gene Transfer of Receptor Activator of Nuclear Factor‐κB‐Fc Prevents Bone Loss in Ovariectomized Mice
Do‐Hee Kim, Sun Wook Cho, Sun Ju Her, Jae Yun Yang, Sang Wan Kim, Seong Yeon Kim, Chan Soo Shin · 2006 · Stem Cells
Human mesenchymal stem cells as delivery of osteoprotegerin gene: homing and therapeutic effect for osteosarcoma
Qiao, Bo, Shui, Wei, Cai, Li, Guo, Shuquan, Jiang, Dianming · 2015 · Drug Design, Development and Therapy
RANKL signaling in bone physiology and cancer
William C. Dougall · 2007 · Current Opinion in Supportive and Palliative Care
Rôle de la triade RANK/RANKL/ostéoprotégérine (OPG) dans les cancers primitifs et secondaires de l’os : aspects physiopathologiques et implications cliniques
Philippe Clézardin · 2011 · Bulletin du Cancer
Systemic Osteoprotegerin Gene Therapy Restores Tumor-induced Bone Loss in a Therapeutic Model of Breast Cancer Bone Metastasis
Diptiman Chanda, Tatyana Isayeva, Sanjay Kumar, Gene P. Siegal, April Adams Szafran, Kurt R. Zinn, Vishnu Reddy, Selvarangan Ponnazhagan · 2008 · Molecular Therapy
Expression of receptor activator of NF-?B ligand (RANKL) mRNA in human multiple myeloma cells
Ulrike Heider, Ivana Zavrski, Christian Jakob, Katharina B�ngeroth, Claudia Fleissner, Corinna Langelotz, Kurt Possinger, Lorenz Christian Hofbauer, Volker Viereck, Orhan Sezer · 2004 · Journal of Cancer Research and Clinical Oncology
Bone Disease in Multiple Myeloma
Homare Eda, Loredana Santo, G. David Roodman, Noopur S Raje · 2016 · Cancer treatment and research
Osteoprotegerin and receptor activator of nuclear factor-kappaB ligand mRNA expression in patients with rheumatoid arthritis and healthy controls.
Ann VanderBorght, Loes Linsen, Marielle M. Thewissen, Piet Geusens, Jef Raus, Piet Stinissen · 2004 · PubMed
Formulation and in vitro and in vivo evaluation of a new osteoprotegerin–chitosan gel for bone tissue regeneration
Soher Nagi Jayash, Najihah Mohd Hashim, Misni Misran, Nor Adinar Baharuddin · 2016 · Journal of Biomedical Materials Research Part A
Drug targets and resistance mechanisms in multiple myeloma
Janine Naß, Thomas Efferth · 2018 · Cancer Drug Resistance
Treating cancer-related hypercalcemia with gallium nitrate.
Brian R Leyland-Jones · 2004 · PubMed
Metastatic Bone Disease
Janet Elizabeth Brown, Robert Edward Coleman · 2003 · American Journal of Cancer
Painful Boney Metastases
Howard S. Smith, Intikhab Mohsin · 2013 · The Korean journal of pain
Evidence of a role for RANKL in the development of myeloma bone disease
E DELEENHEER · 2004 · Current Opinion in Pharmacology
Engineering small-molecule and protein drugs for targeting bone tumors
Yixian Wang, Chenhang Wang, Xia Meng, Zeru Tian, Joseph Zhou, Julian Meyer Berger, Xiang H.-F. Zhang, Han Xiao · 2024 · Molecular Therapy
Gene therapy with human osteoprotegerin decreases callus remodeling with limited effects on biomechanical properties
Michael Ulrich‐Vinther, Edward M. Schwarz, Finn Skou Pedersen, Kjeld Søballé, Troels Torp Andreassen · 2005 · Bone
Advances in Multiple Myeloma and Spine Disease
Tahir Latif, Mohamad A. Hussein · 2005 · Clinical Lymphoma & Myeloma
Managing metastatic bone pain: New perspectives, different solutions
Iwona Zaporowska-Stachowiak, J Łuczak, Karolina Hoffmann, Katarzyna Stachowiak-Szymczak, Wiesław Bryl, Maciej Sopata · 2017 · Biomedicine & Pharmacotherapy
RANK, RANKL and OPG Expression in Breast Cancer – Influence on Osseous Metastasis
Jasmin Teresa Ney, Tanja Natascha Fehm, Ingolf Juhasz-Böess, Erich‐Franz Solomayer · 2012 · Geburtshilfe und Frauenheilkunde
Osteolytic bone diseases: physiological analogues of bone resorption effectors as alternative therapeutic tools
Dominique Heymann, Yannick Fortun, Françoise Rédiní, Marc Padrines · 2005 · Drug Discovery Today